Arrhythmias & electrophysiologyRandomised controlled trial
Edoxaban antithrombotic therapy in diabetic patients with atrial fibrillation and stable coronary artery disease: the EPIC-CAD trial
- randomized trial
Authors' conclusion
The risk of primary outcome was similar between diabetic and non-diabetic patients with AF and CAD. Irrespective of diabetes status, edoxaban monotherapy led to a lower risk of a primary outcome at 12 months than dual antithrombotic therapy.
Study context
- Population
- Patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), analysed by diabetes statusrandomized patients, 421 (40.5%) had diabetes · diabetes 421
- Participants
- 1,040 patients
- Comparison
- edoxaban monotherapy with dual antithrombotic therapy (edoxaban plus a single antiplatelet agent), according to diabetes status
- diabeticn = 421
- Primary endpoint
- Composite of:
- Death from any cause
- Myocardial infarction
- Stroke
- Systemic embolism
- Unplanned urgent revascularization
- Major or clinically relevant non-major bleeding
- Follow-up
- 12 months
Primary result
As reported in the abstract
Hazard ratio (95% CI)P value
diabetic vs non-diabetic
0.82(0.56–1.20)
P = 0.30edoxaban monotherapy vs dual antithrombotic therapydiabetic patients: 6.3% vs. 13.7%
0.44(0.23–0.83)
P = 0.01edoxaban monotherapy vs dual antithrombotic therapynon-diabetic patients: 6.7% vs. 16.3%
0.39(0.23–0.65)
P < 0.001Original publication
Edoxaban antithrombotic therapy in diabetic patients with atrial fibrillation and stable coronary artery disease: the EPIC-CAD trial. Europace. Published 3 September 2026. doi:10.1093/europace/euag247
Summarised from the published abstract; every number is checked against it